On Wednesday, Leerink Partners adjusted their outlook on Quest Diagnostics (NYSE:DGX), increasing the price target to $165 from $160, while maintaining a Market Perform rating. The revised target reflects a valuation of approximately 17 times the firm's calendar year 2025 earnings per share estimate, up from the previous multiple of around 16 times.
Quest Diagnostics reported a strong quarter, attributed to high utilization rates and robust base business growth. Management has emphasized that the company is seeing benefits from recent hospital outreach deals and expanded payer relationships.
Despite these positive developments, Quest Diagnostics experienced a slight decline in adjusted EBIT margins, which fell by about 110 basis points year-over-year. This decrease was partly due to the impact of adverse weather conditions and the Crowdstrike (NASDAQ:CRWD) outage, as well as ongoing wage inflation and the financial mix resulting from recent acquisitions.
The most significant margin pressures came from wage inflation and the mix of deals, notably the substantial contribution from LifeLabs. While these deals are strategically sound, they also reflect the inflationary challenges that Quest Diagnostics is striving to manage.
Leerink Partners noted that while the company is contending with persistent wage inflation and lower-margin deals, there are no major concerns that were not already anticipated by the market.
Looking forward, management's preliminary commentary for fiscal year 2025 sets a solid baseline against multi-year targets. The company's pace of deal-making and high single-digit EPS growth are seen as reasonable expectations for the future.
However, Leerink believes that the potential for upside catalysts is largely reflected in the current stock price, suggesting a balanced risk/reward scenario for a company that is performing well operationally.
In summary, Leerink Partners has raised their price target on Quest Diagnostics to $165 from $160 and reaffirmed a Market Perform rating. The firm has also adjusted its estimates to account for timing changes related to costs and non-operational items.
In other recent news, Quest Diagnostics has been making significant strides in its financial performance and market presence. The healthcare company reported robust growth in the third quarter of 2024, with total revenues reaching $2.49 billion, an 8.5% increase year-over-year.
This growth was driven by organic expansion and strategic acquisitions, including the purchase of LifeLabs, which expanded the company's footprint in the Canadian market.
Furthermore, Baird, a financial services firm, upgraded Quest Diagnostics stock from Neutral to Outperform, citing a positive outlook on the healthcare sector's momentum and several favorable trends benefitting the company. The firm's analysis suggests that if the Federal Reserve pursues a path of prolonged interest rate cuts, companies like Quest Diagnostics have historically outperformed.
Despite weather disruptions and operational challenges, Quest Diagnostics provided an upbeat full-year 2024 guidance with projected revenues between $9.8 billion and $9.85 billion and adjusted earnings per share (EPS) of $8.85 to $8.95. These recent developments underscore the company's strong position and potential for further growth.
InvestingPro Insights
Quest Diagnostics' recent performance aligns with several key metrics and insights from InvestingPro. The company's market cap stands at $17.64 billion, reflecting its significant presence in the Healthcare Providers & Services industry. Quest's P/E ratio of 19.82 suggests a relatively high valuation, which is consistent with Leerink Partners' assessment of the stock's balanced risk/reward scenario.
InvestingPro Tips highlight Quest's financial stability and shareholder-friendly policies. The company has maintained dividend payments for 21 consecutive years and has raised its dividend for 13 consecutive years, demonstrating a commitment to returning value to shareholders. This aligns with the company's solid performance and management's strategic focus on growth through acquisitions and expanded payer relationships.
The revenue growth of 2.6% over the last twelve months and a more robust 8.41% growth in the most recent quarter support the article's mention of strong utilization rates and base business growth. Additionally, Quest's operating income margin of 14.32% reflects the company's ability to generate profits despite the margin pressures discussed in the article.
For investors seeking more comprehensive analysis, InvestingPro offers 10 additional tips for Quest Diagnostics, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.